Probiotic Intervention and Its Influence on Serum Leucine-Rich Alpha-2 Glycoprotein 1 Levels in Acne Vulgaris Patients

Benha University

Status: Completed

Conditions: Influence; Acne Vulgaris; Probiotic; Serum Leucine-Rich Alpha-2 Glycoprotein 1

Treatments: Diagnostic Test: Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) level

Study type: Observational

Funder types: Other

Identifiers

NCT07277075

40-10-2024

Details and patient eligibility

About

This study aimed to assess the serum level of Leucine-rich alpha-2 glycoprotein 1 (LRG1) in Acne vulgaris (AV) individuals and evaluate the effect of probiotic therapy on these serum levels.

Full description

Acne vulgaris (AV) is a common inflammatory disorder of the pilosebaceous units, characterized by the presence of inflammatory, non-inflammatory, or a combination of both types of lesions.

Recent attention has turned toward biomarkers that reflect the inflammatory activity in acne and might act as indicators of disease severity, treatment response, or prognostic risk. One such candidate is Leucine-rich alpha-2 glycoprotein 1 (LRG1).

Probiotics are live microorganisms that, when administered in sufficient quantities, can modulate the composition of the gut microbiota, helping reduce microbial dysbiosis, regulate the immune response, and decrease inflammatory mediators, thereby reducing systemic inflammatory burden, which is called the gut-skin-axis relationship.

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥18 years.
• Both sexes.
• Had not used systemic or topical acne therapy for at least two months or two weeks before the research, respectively.
• Participants with clinically diagnosed mild to moderate acne vulgaris (AV) based on the Global Acne Grading System (GAGS)

Exclusion criteria

• Pregnancy.
• Lactation.
• History of hypersensitivity to probiotic components.
• Smoking.
• Presence of infections.
• Autoimmune or malignant diseases.
• Receiving any systemic therapy likely to affect the microbiome or inflammatory biomarkers.

Trial design

50 participants in 2 patient groups

Study group

Description:

Participants with clinically diagnosed mild to moderate acne vulgaris (AV) based on the Glycosaminoglycans (GAGs).

Treatment:

Diagnostic Test: Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) level

Control group

Description:

Apparently healthy controls matched for age and sex

Treatment:

Diagnostic Test: Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) level